Sutro Biopharma, Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 9, 2021 and accepted by EDGAR at Aug 6, 2021, 17:36 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $28.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $42.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2021-04-01 to 2021-06-30 | $25.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $47.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$9.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$28.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$6.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | −$36.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-04-01 to 2021-06-30 | −$0.13 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2021-01-01 to 2021-06-30 | −$0.79 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-04-01 to 2021-06-30 | −$0.13 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2021-01-01 to 2021-06-30 | −$0.79 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-04-01 to 2021-06-30 | 46,116,175 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2021-01-01 to 2021-06-30 | 46,007,892 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | −$35.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2021-06-30 | $56.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $277.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $359.8m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $26.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $52.3m | us-gaap:Liabilities |
| Long-term debt | At period end2021-06-30 | $21.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2021-06-30 | $3.1m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2021-06-30 | $307.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-21-042217. Last ingested by Listed: Nov 13, 2026, 16:35 ET. Listed shows no prices and gives no investment advice.